PlantEXT

Company Overview

Snapshot

Founded in December 2015 by Oded Sagee, PlantEXT operates with 1–10 employees. The company has raised $5.6 million across three funding rounds. In October 2020, PlantEXT announced the appointment of Willy Kruh as Chief Executive Officer, signaling a strategic leadership transition.

Business overview

PlantEXT specializes in the discovery and development of active cannabis extracts, focusing on anti-inflammatory remedies. The company's technology isolates therapeutic elements at a molecular level and quantifies anti-inflammatory activity through in-vitro and ex-vivo studies. PlantEXT is currently launching its first line of IBD medical cannabis products in Israel, with plans for international expansion and the development of additional medical products for indications such as psoriasis, atopic dermatitis, arthritis, pain, and migraines. The company operates within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology, Medical Cannabis, and Drugs Discovery & Development.

Strategic signal

In October 2020, PlantEXT announced that it had isolated cannabis compounds with the potential to decrease inflammation in the cytokine storm associated with COVID-19, in collaboration with the Agricultural Research Organization (ARO-Israel). This development highlights the company's ongoing research into the therapeutic applications of cannabis beyond its initial focus areas, suggesting a potential expansion into critical care or infectious disease support, which could attract broader investor interest and strategic partnerships.

Company Intelligence Q&A

What is PlantEXT's primary focus in product development?

PlantEXT is focused on discovering and developing active cannabis extracts for anti-inflammatory remedies, utilizing in-vitro and ex-vivo studies to quantify anti-inflammatory activity.

When was Willy Kruh appointed as CEO of PlantEXT?

PlantEXT announced the appointment of Willy Kruh as Chief Executive Officer in October 2020.

What significant research collaboration did PlantEXT announce in October 2020?

In October 2020, PlantEXT and the Agricultural Research Organization (ARO-Israel) announced the isolation of cannabis compounds that potentially decrease inflammation in the cytokine storm of COVID-19.

What is PlantEXT's current product launch strategy?

PlantEXT is currently launching its first line of IBD medical cannabis products in Israel and plans to follow with international expansion and the launch of further medical products for additional indications such as psoriasis, atopic dermatitis, arthritis, pain, and migraines.

Did PlantEXT engage in any brokered private placements?

In July 2019, PlantEXT engaged Beacon Securities Limited for a $7 million USD brokered private placement.